CURE continues to be an important supporter of the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Winship Cancer Institute at Emory University as well as other leading pediatric cancer research institutions across the nation. Through generosity of donors, CURE is able to provide more than $4 million in annual support to promising research projects.
For the current fiscal year, we are funding 17 specific projects, including our largest single grant to date – a $1.5 million award for the development of the Aflac Cancer Center Precision Medicine Program. The program envisions personalized, non-toxic and curative cancer therapy for all children.
In addition to the Precision Medicine Program, CURE is awarding another $1.26 million to projects at the AFLAC Cancer Center and $1.3 million at centers of excellence around the country.

AFLAC Cancer & Blood Disorders, Emory University
Graham, Douglas MD, PhD
Aflac Cancer Center Precision Medicine Program
Spencer, H. Trent PhD
Manufacturing of a GMP compliant T-cell product to treat high risk neuroblastoma
Porter, Christopher C, MD
Targeting Siglee15 for the treatment of childhood leukemia
MacDonald, Tobey MD
Combined CSF-1R and STAT3 Inhibition as a Novel Immunotherapeutic Strategy for Medulloblastoma
Gu, Lubing MD
MDM4-TOP2A interaction as potential target for treatment of pediatric cancers
Kenney, Anna PhD/Dey
Targeting YB1 to prevent post-radiation medulloblastoma recurrence
Zhou, Muxiang MD
Targeting MYCN mRNA for treatment of MYCN-amplified neuroblastoma of children
Van Meir, Erwin PhD
Investigating the tumor suppressor function of BAI3 in WNT medulloblastoma
Graham, Doug and DeRyckere, Deborah
MERTK Inhibitor Combination Therapy for Treatment of AML
Cash, Thomas MD, MSc
A Phase I Study of 131I-MIBG with Dinutuximab for Relapsed/Refractory neuroblastoma
Sabnis, Himalee MD, MSc
ENCERT: A Phase 1 Trial using Everolimus in combination with Nelarabine, Cyclophosphamide and Etoposide in Relapsed T-cell Lymphoblastic Leukemia/Lymphoma
Children’s Oncology Group & Fred Hutchinson Cancer Research Center
Meshinchi, Soheil MD, PhD
Target Pediatric AML
Children’s Cancer Therapy Development Institute
Keller, Charles MD
Prediction & Validation of a Novel Drug Combination Against Anaplastic Wilms’ tumor
Dana-Farber Cancer Institute
DuBois, Steven MD MS
Phase 1 Trial of Dual PI3K/BRD4 Inhibitor for Children with Neuroblastoma
Seattle Children’s Hospital
Kean, Leslie MD
A First-in-Disease Phase II Trial of T-cell Costimulation Blockade for GVHD Prevention
The Children’s Hospital of Philadelphia
Felix, Carolyn MD
Mechanism-Based Prevention of TOP2-Poison Related Leukemia
The University of Utah
Jones, Kevin
Epigenetic Drivers of Clear Cell Sarcoma